#### Sun Pharmaceutical Industries Limited

SUN HOUSE, Plot No. 201 B/1,

Western Express Highway, Goregaon (E),

Mumbai 400063, India

Tel.: (91-22) 4324 4324 Fax.: (91-22) 4324 4343

Website: <a href="www.sunpharma.com">www.sunpharma.com</a> Email: <a href="mailto:secretarial@sunpharma.com">secretarial@sunpharma.com</a> CIN: L24230GJ1993PLC019050



January 17, 2025

National Stock Exchange of India Limited BSE Limited

Scrip Symbol: SUNPHARMA Scrip Code: 524715

Subject: Press Release- Sun Pharma to announce third quarter results on January 31, 2025

Enclosed herewith is a copy of the Press Release relating to the Earnings Call for financial results for the third quarter ending December 31, 2024, which we shall be releasing after sending this letter to you.

For Sun Pharmaceutical Industries Limited

(Anoop Deshpande)

Company Secretary and Compliance Officer
ICSI Membership No.: A23983

Reaching People. Touching Lives

#### Sun Pharmaceutical Industries Limited

SUN HOUSE, Plot No. 201 B/1,

Western Express Highway, Goregaon (E),

Mumbai 400063, India

Tel.: (91-22) 4324 4324 Fax.: (91-22) 4324 4343

Website: <a href="www.sunpharma.com">www.sunpharma.com</a> Email: <a href="mailto:secretarial@sunpharma.com">secretarial@sunpharma.com</a> CIN: L24230GJ1993PLC019050



# **FOR IMMEDIATE RELEASE**

# Sun Pharma to announce third quarter results on January 31, 2025

January 17, 2025, Mumbai: Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) will announce results for the third quarter ended December 31, 2024, on January 31, 2025. These results will also be available on the Company website, www.sunpharma.com.

Earnings call (06.30 pm IST, January 31, 2025)

The Company will conduct an hour-long call at 06.30 pm IST on January 31, 2025, where senior management will discuss the Company's performance and answer questions from participants. To participate in this conference call, please pre-register yourself on the below link and dial the numbers provided below, five to ten minutes ahead of the scheduled start time. The operator will provide instructions on asking questions before the call. You can also hear the call via an audio webcast, details of which will be announced later on the Company website, <a href="https://www.sunpharma.com">www.sunpharma.com</a>. A transcript of this conference call will also be available on the website.

### **Summary of events**

Event	Date and time	Telephone number/ website
Earnings release	January 31, 2025	www.sunpharma.com
Earnings conference call	06.30 pm IST, January 31, 2025	Universal Number: +91 22 6629 0049 +91 22 7194 5729  Via audio webcast, details of which will be made available on <a href="https://www.sunpharma.com">www.sunpharma.com</a>
Pre-registration details (to avoid wait time)		Click here for <u>DiamondPassRegistration</u>

## **Disclaimer:**

Statements in this "Document" describing the Company's objectives, projections, estimates, expectations, plans or predictions or industry conditions or events may be "forward looking statements" within the meaning of applicable securities laws and regulations. Actual results, performance or achievements could differ materially from those expressed or implied. The Company undertakes no obligation to update or revise forward looking statements to reflect developments or circumstances that arise or to reflect the occurrence of unanticipated developments/circumstances after the date hereof.

### Sun Pharmaceutical Industries Limited

SUN HOUSE, Plot No. 201 B/1,

Western Express Highway, Goregaon (E),

Mumbai 400063, India

Tel.: (91-22) 4324 4324 Fax.: (91-22) 4324 4343

Website: <a href="www.sunpharma.com">www.sunpharma.com</a> Email: <a href="mailto:secretarial@sunpharma.com">secretarial@sunpharma.com</a> CIN: L24230GJ1993PLC019050



### About Sun Pharmaceutical Industries Limited (CIN - L24230GJ1993PLC019050):

Sun Pharma is the world's leading specialty generics company with a presence in Specialty, Generics and Consumer Healthcare products. It is the largest pharmaceutical company in India and is a leading generic company in the US as well as Global Emerging Markets. Sun's high growth Global Specialty portfolio spans innovative products in dermatology, ophthalmology, and onco-dermatology and accounts for over 18% of company sales. The company's vertically integrated operations deliver high-quality medicines, trusted by physicians and consumers in over 100 countries. Its manufacturing facilities are spread across six continents. Sun Pharma is proud of its multi-cultural workforce drawn from over 50 nations. "For further information, please visit www.sunpharma.com and follow us on LinkedIn & X (Formerly Twitter)."

#### **Contacts:**

Investors: Media: Dr. Abhishek Sharma Gauray G

Dr. Abhishek Sharma

Gaurav Chugh

Tel +91 22 4324 4324, Xtn 2929

Tel +91 22 4

Tel Direct +91 22 4324 2929 Mobile +91 98196 86016

E mail <u>abhi.sharma@sunpharma.com</u>

Tel +91 22 4324 4324, Xtn 5373

Tel Direct +91 22 4324 5373 Mobile +91 98104 71414

E mail gaurav.chugh@sunpharma.com